Joanne M Donovan: Influence Statistics

Joanne M Donovan

Joanne M Donovan

Genzyme Corporation, Cambridge, MA, USA | Genzyme Corporation, Cambridge, MA 02142, USA | From the Metabolic and Atherosclerosis Research Center, Cincinnati, OH (E.A.S.); ...

Joanne M Donovan: Expert Impact

Concepts for which Joanne M Donovan has direct influence: Colesevelam hcl , Primary hypercholesterolemia , Colesevelam hydrochloride , Hdl cholesterol , Plasma glucose , Cholesterol ldl , Bile acid .

Joanne M Donovan: KOL impact

Concepts related to the work of other authors for which for which Joanne M Donovan has influence: Familial hypercholesterolemia , Colesevelam hcl , Statin therapy , Type 2 diabetes , Bile acid sequestrants , Cholesterol ldl , Density lipoprotein .

KOL Resume for Joanne M Donovan

Year
2014

Genzyme Corporation, Cambridge, MA, USA

2012

Genzyme Corporation, Cambridge, MA 02142, USA

Portland, OR

2010

Genzyme Corporation, Genzyme Center, Cambridge, Massachusetts, USA

2009

Vice President, Clinical Research, Genzyme Corporation, Waltham, MA

2005

Genzyme Drug Discovery and Development, 153 Second Avenue, 02451, Waltham, Massachusetts, USA

2001

GelTex Pharmaceuticals Inc., 153 Second Avenue, Waltham, MA 02451, USA

Prominent publications by Joanne M Donovan

KOL-Index: 13601 . BACKGROUND: Colesevelam hydrochloride is a novel, lipid-lowering agent that binds bile acids with high affinity. A multicenter, randomized, double-blind, placebo-controlled, parallel-design study was conducted to assess the efficacy and tolerability of combination low-dose colesevelam and lovastatin treatment in patients with primary hypercholesterolemia. HYPOTHESIS: Combination therapy ...
Known for Colesevelam Hydrochloride | Primary Hypercholesterolemia | Combination Therapy | Lovastatin Dinner
KOL-Index: 12379 . BackgroundColesevelam is a bile acid sequestrant that differs structurally from traditional bile acid sequestrants, allowing it to bind bile acids with greater affinity. Studies have shown that colesevelam significantly reduces low-density lipoprotein cholesterol (LDL-C) levels and, in some cases, significantly increases high-density lipoprotein cholesterol (HDL-C) levels in adults with ...
Known for Hdl Cholesterol | Ldlc Levels | Ldl Colesevelam | 375 Day
KOL-Index: 11641 . AIMS: A randomized, double-blind, placebo-controlled study was conducted to investigate the safety and efficacy of mipomersen, an apolipoprotein B-100 (apoB) synthesis inhibitor, in patients who are statin intolerant and at high risk for cardiovascular disease (CVD). METHODS AND RESULTS: Thirty-three subjects, not receiving statin therapy because of statin intolerance, received a weekly ...
Known for Intolerant Patients | Placebo Mipomersen | Lipoprotein Cholesterol | Risk Cvd
KOL-Index: 11164 . BACKGROUND: Heterozygous familial hypercholesterolemia (HeFH) is a common genetic disorder leading to premature coronary artery disease. Despite statins and additional lipid-lowering therapies, many HeFH patients fail to achieve low-density lipoprotein cholesterol (LDL-C) goals. We evaluated mipomersen, an apolipoprotein B synthesis inhibitor, to further lower LDL-C in HeFH patients with ...
Known for Hefh Patients | Mipomersen Ldlc | Heterozygous Familial | Hepatic Fat
KOL-Index: 10939 . PURPOSE: To examine the efficacy and safety of colesevelam hydrochloride, a novel, nonsystemic, lipid-lowering agent, when coadministered with starting doses of simvastatin in a multicenter, randomized, double-blind, placebo-controlled trial. PATIENTS AND METHODS: Subjects with hypercholesterolemia (plasma low density lipoprotein [LDL] cholesterol level > 160 mg/dL and triglyceride level < ...
Known for Combination Simvastatin | Primary Hypercholesterolemia | Hdl Cholesterol | Efficacy Safety
KOL-Index: 10862 . Colesevelam hydrochloride is a novel, potent, non-absorbed lipid-lowering agent previously shown to reduce low density lipoprotein (LDL) cholesterol. To examine the efficacy and safety of coadministration of colesevelam and atorvastatin, administration of these agents alone or in combination was examined in a double-blind study of 94 hypercholesterolemic men and women (baseline LDL ...
Known for Colesevelam Hydrochloride | Hdl Cholesterol | 4 Weeks | Combination Therapy
KOL-Index: 8584 . OBJECTIVE: To evaluate the efficacy, tolerability, and safety of colesevelam hydrochloride, a new nonsystemic lipid-lowering agent. PATIENTS AND METHODS: In this double-blind, placebo-controlled trial performed in 1998, 494 patients with primary hypercholesterolemia (low-density lipoprotein [LDL] cholesterol level > or = 130 mg/dL and < or = 220 mg/dL) were randomized to receive placebo or ...
Known for Colesevelam Hydrochloride | Primary Hypercholesterolemia | Cholesterol Ldl | Randomized Controlled
KOL-Index: 5632 . Although colesevelam hydrochloride (HCl) is indicated to reduce low-density lipoprotein cholesterol (LDL-C) in patients with hyperlipidemia and improve glycemic control in patients with type 2 diabetes, its effects on glucose and lipids in patients with prediabetes have not been previously studied. To evaluate the effects of colesevelam HCl in patients with prediabetes, a post-hoc analysis ...
Known for Colesevelam Hcl | Plasma Glucose | Glycemic Control | Cholesterol Ldl
KOL-Index: 4617 . Colesevelam HCl is a potent bile acid–binding polymer. This study's aim was to determine effects of colesevelam HCl on sterol and bile acid excretion in patients with type IIa hypercholesterolemia. Twenty-four patients (low-density lipoprotein cholesterol, 130 to 220 mg/dL) enrolled in an open-label, parallel-design study, entered an American Heart Association/National Cholesterol ...
Known for Colesevelam Hcl | Bile Acid | 6 Weeks | Cholesterol Ldl
KOL-Index: 3555 . BACKGROUND: Because of variability in lipoprotein cholesterol content, low-density lipoprotein (LDL) cholesterol frequently underrepresents or overrepresents the number of LDL particles. Mipomersen is an antisense oligonucleotide that reduces hepatic production of apolipoprotein B-100, the sole apolipoprotein of LDL. OBJECTIVE: To characterize the effects of mipomersen on lipoprotein ...
Known for Density Lipoprotein | Cholesterol Ldl | Coronary Heart Disease | Compared Small
KOL-Index: 1956 . Deferitrin, a novel, orally available iron chelator, is in the early stage of clinical development for the treatment of chronic iron overload due to transfusional therapy. Preclinical pharmacology studies demonstrate iron excretion largely by the fecal route. Initial clinical studies have shown deferitrin to be well absorbed. Further clinical studies are ongoing to determine the efficiency ...
Known for Iron Chelator | Molecular Structure | Chelating Agents | Chelation Therapy

Key People For Colesevelam Hcl

Top KOLs in the world
#1
Michael H Davidson
hdl cholesterol schizophrenic patients cognitive impairment
#2
Donald B Hunninghake
hdl cholesterol coronary heart disease lipoprotein levels
#3
Harold Edward Bays
bempedoic acid icosapent ethyl diabetes mellitus
#4
Steven K Burke
sevelamer hydrochloride serum phosphorus hemodialysis patients
#5
Phillip D Toth
colesevelam hydrochloride obese patients moderate hypertension
#6
WILLIAM JR Insull
hdl cholesterol corneal arcus delayed adolescence

Genzyme Corporation, Cambridge, MA, USA | Genzyme Corporation, Cambridge, MA 02142, USA | From the Metabolic and Atherosclerosis Research Center, Cincinnati, OH (E.A.S.); Clinical Research Institute of Montréal, Montréal, Québec, Canada (R.D.); Clini